Fulcrum Therapeutics, Inc. has announced its financial results for the fourth quarter and full year of 2024, reporting a cash position of $241 million, providing a runway into at least 2027. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback